June 25, 2020 / 11:09 AM / 17 days ago

BRIEF-Oncolytics Biotech Announces Phase 2 Trial Evaluating Pelareorep-Anti-Pd-1 Combination Treatment

June 25 (Reuters) - Oncolytics Biotech Inc:

* ONCOLYTICS BIOTECH® ANNOUNCES INVESTIGATOR SPONSORED PHASE 2 TRIAL EVALUATING PELAREOREP-ANTI-PD-1 COMBINATION TREATMENT IN TRIPLE-NEGATIVE BREAST CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below